The 4.27x P/B must be read against an equity base that has already been marked down to $101.1M after $449.5M of accumulated losses, so the premium appears to sit on shrinking net asset value rather than booked earnings power. With no EV/EBITDA or forward earnings available, investors are effectively pricing the present value of future royalty streams; any deterioration in partner program uptake or milestone timing would, on this framing, hit the multiple disproportionately.

Near-constant 100% gross margin tells us almost nothing analytically here, because a licensing-royalty model carries negligible cost of sales and therefore offers no pricing or production signal. The meaningful margin to watch is operating margin, which narrowed from -192.1% in 2024Q2 to -120.0% in 2026Q3, yet that improvement appears traceable to an ~$18M annualized R&D reduction rather than revenue expansion — a trade that arguably trades future pipeline value for near-term burn optics. Stock-based compensation of $3.7M per quarter further means adjusted earning power looks structurally worse than the reported figure.

ROE of -17.9% and ROA of -6.4% in 2026Q3 confirm the company is destroying value on both equity and total-asset bases, with no quarter in the sample producing positive returns on either measure. The slight ROIC improvement from ~-7% to ~-6.6% coincides with total assets falling 28% and debt being retired, which suggests the ratio is flattered by a smaller denominator rather than recovering profitability. Asset turnover of 0.05, versus a typical operating company's materially higher figure, reflects the royalty model's thin revenue per dollar of assets and warns against inferring efficiency from the stable ratio.

Current and quick ratios are identical across all ten quarters, which is consistent with a royalty-revenue model carrying no inventory to convert into cash — that equality also means there is no secondary liquidity buffer behind the reported ratios. The trajectory is more telling than the level: the current ratio has compressed from 6.43 in 2024Q2 to 3.76, and with quarterly net losses running roughly -$19.5M and FCF margin at -69.5%, the cushion appears to be shrinking at a pace that warrants close monitoring of the financing runway. The sharp ~$131M debt reduction between 2026Q2 and 2026Q3 appears to have been funded from reserves, which would explain the simultaneous cash drawdown and argues against reading the deleveraging as an operating-strength signal.

Across the peer set, nearly every company shows negative P/E and absent EV/EBITDA, so earnings-based comparison is non-discriminating; the useful gap is in ROIC, where ENTA's -6.6% sits materially better than Arcus at -63.2% but worse than Achieve at -2.4%, suggesting its royalty revenue provides a more durable loss-buffer than pipeline-stage peers. The 4.27x P/B versus peers at 1.55x–17.00x implies the market assigns ENTA's royalty stream more confidence than cash-burning discovery-stage names, though the peer median is wide enough that this premium is not self-evidently a structural advantage. D/E of 0.55 also stands out as elevated versus peers like Agios, Arcutis and Immunovant at ~0.00–0.03, so ENTA's deleveraging story, while real, remains incomplete relative to the group.